# Breathe BioMedical Inc. — Healthcare Investment Intelligence

> diagnostics. MedFuel Intel profile as of 2026-06-12.

Breathe BioMedical is developing a breath analytics platform for early breast cancer detection in women with dense breast tissue as an adjunct to mammography, with recent research showing 88.2% accuracy in identifying differences between early-stage breast cancer and non-cancer breath signatures.

---
Uploaded Documents:
[From: Breathe BioMedical Overview - Standalone Investor Deck - Apr 2026 USD.pdf | Type: document]
Non-DenseDense The current standard of care forces a massive, unstratified wave of women with dense breast into secondary screening Blanket Referral for Secondary Screening Dense Tissue Diagnosis Overloaded MRI & Ultrasound Infrastructure Systemic consequences Severe resource strain, inflated healthcare costs, and prolonged patient anxiety while awaiting expensive secondary scans. Healthcare Systems do not have the equipment and trained professionals to meet the demand The solution is a simple, non invasive, affordable and accessible breath test for ALL women with dense breast Blanket Referral for Breath Screening Test Dense Tissue Diagnosis Healthcare System does not have the equipment and trained professionals to meet the demand. Faster access to MRI & Ultrasound following a positive breath test Systemic benefits No strain on HC resources, significantly lower healthcare and patient costs, less patient anxiety and more equitable distribution of resources Accruing ahead of schedule Core Objective: Develop an early breast cancer detection algorithm for women with dense breast tissue Accruing at Top Tier Institutions Class I Medical Device Class I Medical Device Class III Medical Device Go to Market US and Canada Dense Breast Screening Mkt. 80M Women 28M Women 14M $7 B $3.5 B Currency denominated in US dollars Total Annual Third party independent research confirms that US payors with 1M lives insured will save $16M annually by avoiding late-stage treatment costs for women with dense breast tissue 2025 - 2027 2030 2032 Currency denominated in US dollars Our patent portfolio covers breath collection methods, spectrometry analysis, and machine learning methods 9 20 Patents 16 Issued & 4 pending 12 Patents 12 pending 50 Patents 3 Issued & 47 pending Canada, Japan, China, India, Australia 100% owned by the company No royalties or milestone payments Long patent runway through 2041 Proven Leadership: 30+ years of Life Sciences commercialization experience Bill Dawes CEO/BDO 30 years scaling life sciences operations. Founding Team & VP at Lantheus (NASDAQ:LNTH); GM at Bristol-Myers Squibb. Don Hardison BOD Ex-CEO Exact Sciences (led IPO), Biotheranostics (Acquired by Hologic); Senior roles at LabCorp and Quest Chris Purves CTO Co-developer of the proprietary Technology; specialized expertise in BioPhotonics and ISO System Implementation. Dr. Rachel Brem CMO/BOD World-renowned breast cancer expert. Has led four diagnostic technologies Successfully through FDA approval. Sandra Veenstra CRO Chief Regulatory Officer; successfully Implemented ISO 13485 quality system; profound expertise in Health Law ComponentStatusRole in 2026 Seed Round Sampler (Class 1 / TRL 8)Deployed The “Breath Collector." Proven safe and easy for nurses to use. Spectrometer (TRL 7)4 Units Active The “Analyzer." Data processing is already online. AI Model– Breast Cancer (TRL 3) In Training The “Breast Cancer BioMarker.“ Use of Proceeds used to collect patient breath samples (Data), where the return lives. Key Value Milestone Funds are exclusively directed toward reaching our clinical value inflection point in Q1 2027, supporting FDA engagement, and early commercialization preparation in Canada and in the US US D Target Raise: $7M USD Structure: Tranche A = $3.5M Pre-money Valuation: $26M Security: Common Shares Issue price: $2.14 Raise & Use of Proceed The target raise of $7M is structured into two $3.5M tranches. Capital to be used to train the AI model on early breast cancer. Early Detection Saves Lives Guiding the right patients to the right exams for early detection and cure. Find more cancers with fewer tests and prevent late-stage disease

## Key facts (as of 2026-06-12)
- Sector: diagnostics
- Website: https://breathebiomedical.com/

## MedFuel assessment
- Intelligence score: 15/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/breathe-biomedical-inc. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.